Focus Partners Wealth Takes Position in DexCom, Inc. (NASDAQ:DXCM)

Focus Partners Wealth acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,377 shares of the medical device company's stock, valued at approximately $496,000.

Other institutional investors have also added to or reduced their stakes in the company. Private Trust Co. NA raised its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. acquired a new position in shares of DexCom during the fourth quarter worth $33,000. TD Private Client Wealth LLC increased its holdings in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth $38,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This trade represents a 8.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at $10,002,636.06. This trade represents a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock worth $4,734,384 over the last quarter. Company insiders own 0.32% of the company's stock.

DexCom Price Performance

Shares of DXCM traded down $0.32 during mid-day trading on Friday, reaching $84.51. 2,599,337 shares of the stock traded hands, compared to its average volume of 4,363,730. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $128.63. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The company has a market cap of $33.14 billion, a price-to-earnings ratio of 59.10, a price-to-earnings-growth ratio of 2.30 and a beta of 1.43. The firm has a fifty day moving average price of $73.54 and a 200 day moving average price of $78.13.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.32 EPS. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the subject of several research analyst reports. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and upped their price target for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Barclays upped their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a report on Monday, May 5th. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research upgraded shares of DexCom to a "hold" rating in a report on Friday, March 21st. Finally, Piper Sandler decreased their price objective on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.